Apcelera shares surge 22% on positive Phase 2 results for ABCL635

ABCL AbCellera Biologics Inc

$12.50 +5.22%

View chart & analysis →

1. 1Apcelera (ABCL) shares jumped 22% after announcing positive topline Phase 2 results for its candidate ABCL635, being developed to treat moderate-to-severe vasomotor symptoms in menopause.
2. 2In a trial of 92 postmenopausal women receiving a single 600mg subcutaneous dose, the ABCL635 group showed 5.3 fewer daily symptom episodes at week 4 versus placebo, along with a 1.1-point improvement in severity.
3. 3The study met its primary efficacy endpoint, and demonstrated good tolerability with no serious adverse events, supporting clinical validation of a non-hormonal, long-acting therapeutic option.

Source InvestorsHub +1 · View original ↗

Today's 5 AI picks, all free

Nothing hidden: past picks and how they did against the S&P 500.

See today's picks →